

composition, and ethanol or propylene glycol in an amount of from about 1 to about 15 weight % of the composition;

- (c) water in an amount of from about 0.4 to about 3.5 weight % of the composition; and
- (d) optionally, a pharmaceutically acceptable surfactant.

4. (twice amended) The composition according to Claim 1 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) and another HIV protease inhibiting compound selected from the group consisting of:

(2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ( indinavir );

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide ( saquinavir );

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;




1-Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)-3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;




[1S-[1R-(R-),2S\*]]-N<sup>1</sup> [3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-

US 09/576,097  
Amendment and Response  
February 3, 2003


hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;




US 09/576,097  
Amendment and Response  
February 3, 2003



US 09/576,097  
Amendment and Response  
February 3, 2003



; and



or a pharmaceutically acceptable salt thereof.

8. (once amended) The composition of Claim 1 wherein the solvent comprises (1) a pharmaceutically acceptable long chain fatty acid in an amount of from about 40 to about 75 weight % of the composition; (2) ethanol or propylene glycol in an amount of from about 3 to about 12 weight % of the composition; and (3) water in an amount of from about 0.4 to about 1.5 weight % of the composition.

9. (once amended) The composition of Claim 1 wherein the solvent comprises (1) oleic acid in an amount of from about 40 to about 75 weight % of the composition; (2) ethanol or propylene glycol in an amount of from about 3 to about 12 weight % of the composition; and (3) water in an amount of from about 0.4 to about 1.5 weight % of the composition.

10. (twice amended) The composition of Claim 9 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-

US 09/576,097  
Amendment and Response  
February 3, 2003

thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ( indinavir );

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginy]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide ( saquinavir );





5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;




5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S\*] ]-N<sup>1</sup> [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;


US 09/576,097  
Amendment and Response  
February 3, 2003



US 09/576,097  
Amendment and Response  
February 3, 2003



; and



US 09/576,097  
Amendment and Response  
February 3, 2003


or a pharmaceutically acceptable salt thereof.

11. (twice amended) The composition of Claim 9 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl-butanoyl)- amino-1,6-diphenylhexane,


N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ( indinavir ),

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylylcarbonyl)-L-asparaginyllamino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide ( saquinavir ),




US 09/576,097  
Amendment and Response  
February 3, 2003





and



or a pharmaceutically acceptable salt thereof.

14. (twice amended) The composition of Claim 1 which comprises:

(a) solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) in an amount of from about 1 to about 30 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 30 to about 75 weight % of the composition and (2) ethanol in an amount of from about 3 to about 12 weight % of the composition; and

(c) water in an amount of from about 0.4 to about 3.5 weight % of the composition; and

(d) polyoxyl 35 castor oil in an amount of from about 0 to about 20 weight % of the composition.

15. (twice amended) A pharmaceutical composition comprising:

US 09/576,097  
Amendment and Response  
February 3, 2003

(a) (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) in an amount of about 10 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 70 to about 75 weight % of the composition; and (2) ethanol in an amount of from about 3 to about 12 weight % of the composition;

(c) water in an amount of from about 0.4 to about 1.5 weight % of the composition; and

(d) polyoxyl 35 castor oil in an amount of about 6 weight % of the composition.

17. (twice amended) The composition of Claim 1 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)- amino-1,6--diphenylhexane in an amount of from about 1 to about 45 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 30 to about 75 weight % of the composition and (2) propylene glycol in an amount of from about 1 to about 15 weight % of the composition; and

(c) water in an amount of from about 0.4 to about 3.5 weight % of the composition.

18. (twice amended) The composition of Claim 17 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane ( ritonavir ) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl) amino-1,6-diphenylhexane in an amount of from about 1 to about 45 weight % of the composition;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an amount of from about 70 to about 75 weight % of the composition; and (2) propylene glycol in an amount of from about 1 about 8 weight % of the composition;

(c) water in an amount of from about 0.4 to about 1.5 weight % of the composition; and

US 09/576,097  
Amendment and Response  
February 3, 2003